Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiflam in Long COVID
NCT06437223Phase 2Completed
- Sponsor
- InflammX Therapeutics, Inc.
- Start
- Mar 2024
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
A Phase 2 trial of tonabersat in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by InflammX Therapeutics, Inc.. Started Mar 2024; status: completed.
02
Drugs
tonabersat
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06437223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06437223.